Stem Cell Network Warns that Claims of Stem Cell Treatments for COVID-19 Are Unfounded and Misleading

OTTAWA, March 31, 2020 (GLOBE NEWSWIRE) — In recent weeks, a number of claims have been made that stem cells can be used as a treatment for the coronavirus disease (COVID-19). Globally, there is no clinically tested and government approved stem cell-based treatment for COVID-19.
The Stem Cell Network (SCN) urges extreme caution to those who are considering purchasing products or services advertised as a preventative or curative treatment for COVID-19. In alignment with other international stem cell and regenerative medicine organizations, SCN strongly opposes the marketing of unproven therapies and urge consumers and patients to consult with their doctor or specialist if they have questions or concerns about their health. The best way to combat the spread COVID-19 is to follow the careful advice given by Canada’s Chief Public Health Officer.Researchers across the globe are collaborating and working hard to find legitimate treatments for COVID-19, but this will take time. It is important to note that when a treatment does become available, it will be announced through recognized medical authorities, such as the World Health Organization, which is coordinating global efforts and actively compiling a database of published research on COVID-19.For the most up-to-date information on COVID-19, please consult:
World Health Organization
Public Health Agency of Canada
To learn more about clinical trials or stem cells:
Stem Cell Network Clinical Trial FAQs
Closer Look at Stem Cells
About the Stem Cell Network
Tomorrow’s health is here. The Stem Cell Network (SCN) is a national non-profit that supports stem cell and regenerative medicine research, training the next generation of highly qualified personnel, and delivering outreach activities across Canada. SCN’s goal is to advance science from the lab to the clinic for the benefit of Canadians. SCN has been supported by the Government of Canada since inception in 2001. This strategic funding, valued at $118M has benefitted approximately 170 world-class research groups and 3,000 trainees and has catalyzed 23 clinical trials. stemcellnetwork.ca
Media contact:
Lisa Willemse, Director of Communications & Public Affairs
Stem Cell Network 613-402-3974

CBJ Newsmakers

Recommended
NUTRITIONAL HIGH ANNOUNCES CLOSING OF NON-BROKERED PRIVATE PLACEMENT OF SECURED CONVERTIBLE DEBENTURESSouth Grass Valley Project - March 2020 Drilling Update